Here's Why Madrigal Pharmaceuticals Fell 39.4% in November


Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.... Read more

Bron: Fool.com: The Motley Fool
Tags:
Geplaatst: 08 Dec 2018 - 21:03